HCAT Stock Recent News

Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The mean of analysts' price targets for Health Catalyst (HCAT) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.

Health Catalyst reported strong Q4 results, meeting guidance and showing growth in technology and professional services revenue. The drop in HCAT's share price presents a buying opportunity, as the company's growth initiatives, such as its TEMS offering and next-gen data platform, are expected to drive growth and margin expansion. HCAT's long-term guidance of exceeding $100 million in EBITDA by FY28 is achievable, and its valuation should improve as it demonstrates execution and margin expansion.

The heavy selling pressure might have exhausted for Health Catalyst (HCAT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Health Catalyst, Inc. (HCAT) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.05 per share a year ago.

Beyond analysts' top -and-bottom-line estimates for Health Catalyst (HCAT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

SALT LAKE CITY, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2023 operating results on Thursday, February 22, 2024, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.